Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZE2209 in Advanced Solid Tumors
NCT06248697Phase 1Recruiting
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Jan 2023
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZE 2209 in solid tumor, non-small cell lung cancer (NSCLC) and mesothelioma, sponsored by Shanghai Cell Therapy Group. Primary endpoint: Dose-limiting toxicity at 28 days. Started Jan 2023; status: recruiting.
02
Drugs
BZE 2209
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NCT06248697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248697.